$37.66
4.90% yesterday
Nasdaq, Nov 20, 10:18 pm CET
ISIN
US4158581094
Symbol
HROW

Harrow Health, Inc. Stock price

$37.66
-4.47 10.61% 1M
+9.59 34.16% 6M
+4.11 12.25% YTD
-4.78 11.26% 1Y
+27.38 266.34% 3Y
+31.36 497.78% 5Y
+31.39 500.16% 10Y
+29.01 335.45% 20Y
Nasdaq, Closing price Thu, Nov 20 2025
-1.94 4.90%
ISIN
US4158581094
Symbol
HROW
Industry

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$1.6b
Net debt
$168.6m
Cash
$74.3m
Shares outstanding
37.0m
Valuation (TTM | estimate)
P/E
negative | 88.0
P/S
5.6 | -
EV/Sales
6.3 | -
EV/FCF
negative
P/B
29.7
Financial Health
Equity Ratio
17.9%
Return on Equity
-25.1%
ROCE
9.4%
ROIC
-
Debt/Equity
5.2
Financials (TTM | estimate)
Revenue
$250.0m | $287.3m
EBITDA
$46.1m | $73.6m
EBIT
$28.1m | $42.1m
Net Income
$-5.0m | $15.8m
Free Cash Flow
$-20.6m
Growth (TTM | estimate)
Revenue
47.8% | 43.9%
EBITDA
1,041.3% | 224.1%
EBIT
427.5% | 363.9%
Net Income
85.1% | 190.6%
Free Cash Flow
-775.1%
Margin (TTM | estimate)
Gross
74.6%
EBITDA
18.4% | 25.6%
EBIT
11.2%
Net
-2.0% | 5.5%
Free Cash Flow
-8.2%
More
EPS
$-0.1
FCF per Share
$-0.6
Short interest
19.4%
Employees
382
Rev per Employee
$520.0k
Show more

Is Harrow Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Harrow Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Harrow Health, Inc. forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Harrow Health, Inc. forecast:

Buy
93%
Hold
7%

Financial data from Harrow Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
250 250
48% 48%
100%
- Direct Costs 64 64
37% 37%
25%
186 186
52% 52%
75%
- Selling and Administrative Expenses 144 144
20% 20%
58%
- Research and Development Expense 14 14
29% 29%
6%
46 46
1,041% 1,041%
18%
- Depreciation and Amortization 18 18
43% 43%
7%
EBIT (Operating Income) EBIT 28 28
428% 428%
11%
Net Profit -4.99 -4.99
85% 85%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Harrow Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Harrow Health, Inc. Stock News

Neutral
GlobeNewsWire
3 days ago
NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition of Melt Pharmaceuticals, Inc. (Melt), a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and i...
Neutral
Seeking Alpha
9 days ago
Harrow, Inc. ( HROW ) Q3 2025 Earnings Call November 11, 2025 8:00 AM EST Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO & Chairman of the Board Andrew Boll - President, CFO & Corporate Secretary Patrick Sullivan - Head of Commercial Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Chase Kni...
Neutral
GlobeNewsWire
10 days ago
Third-Quarter 2025 and Recent Selected Highlights:  Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year period GAAP net income of $1.0 million Adjusted EBITDA of $22.7 million Cash and cash equivalents of $74.3 million as of September 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn.
More Harrow Health, Inc. News

Company Profile

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the Pharmaceutical Compounding and Pharmaceutical Drug Development segments. The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Head office United States
CEO Mark Baum
Employees 382
Founded 2006
Website www.harrow.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today